Revvity, Inc.

Valuation Analysis

About the Company

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for

Revvity, Inc. Stock at a Glance

Revvity, Inc. (RVTY) is currently trading at $99.66 with a market capitalization of $11.1B. The trailing P/E ratio stands at 47.91x, with a forward P/E of 17.12x. The 52-week range spans from $81.22 to $118.30; the current price is 15.8% below the yearly high. Year-over-year revenue growth stands at +7.0%. The net profit margin stands at 8.26%.

💰 Dividend

Revvity, Inc. pays an annual dividend of $0.28 per share, representing a yield of 0.28%. The payout ratio stands at 13.46%.

📊 Analyst Rating

14 analysts rate Revvity, Inc. (RVTY) on consensus: Buy. The average price target is $113.64, implying +14.03% from the current price. Analyst price targets range from $90.00 to $145.00.

Revvity, Inc.: The Investment Case in Detail

Revvity, Inc. (RVTY) operates in the Healthcare — specifically Diagnostics & Research — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bear Case

Short interest sits at 11.75% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong. Our valuation screen flags the stock as overvalued — current multiples imply the business needs to deliver well above its recent trajectory to justify the price.

Valuation in Context

With a PEG ratio of 0.61, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

What to Watch Next

• The forward P/E of 17.12x is meaningfully below the trailing 47.91x — analysts expect earnings to step up; the next earnings release is the test.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to market-like volatility, elevated short interest (11.75%).

Trading Data

💵 Dividend Info

Related Stocks in the Same Sector

Where can I buy Revvity, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.